Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results

BACKGROUND: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy, yet real-world switching data are currently l...

Descripción completa

Detalles Bibliográficos
Autores principales: Argüelles-Arias, Federico, Guerra Veloz, Maria Fernanda, Perea Amarillo, Raul, Vilches-Arenas, Angel, Castro Laria, Luisa, Maldonado Pérez, Belen, Chaaro Benallal, Dina, Benítez Roldán, Antonio, Merino, Vicente, Ramirez, Gabriel, Calleja-Hernández, Miguel Angel, Caunedo Álvarez, Angel, Romero Gómez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2017
Materias:
Original Articles: Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640013/
https://www.ncbi.nlm.nih.gov/pubmed/28902041
http://dx.doi.org/10.1097/MEG.0000000000000953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640013/
https://www.ncbi.nlm.nih.gov/pubmed/28902041
http://dx.doi.org/10.1097/MEG.0000000000000953

Ejemplares similares